Abstract:
Ciprofloxacin is an antibiotic used to treat many cases of bacterial
infection. This includes bone and joint infections and intra-adnominal
injuries infections and some types of infectious diarrhea, respiratory
tract infections and skin infections and typhoid fever, urinary tract
infection and other different types of infection. In some other types of
infection it is used along with other antibiotics.
The method validation is an important issue in pharmaceutical
analysis because the process confirms that the analytical procedure
employed for the analysis is suitable for the intended use and to show
reliability of the method. All the validation parameters for
quantitative analysis of Ciprofloxacin in pharmaceutical formulation
were tested and validation data were evaluated according to their
acceptance criteria. The aim of this work was the validation of
analytical procedure Ciprofloxacin in pharmaceutical formulations
using an ultra – violet (U.V) buffer solution in this method all the
standards and samples solutions were prepared in solvent as (diluents)
and used as the blank solution, the U.V detection was at 276n m, the
calculations of results were treated using excel sheet.
Validation of the proposed method as carried out for accuracy,
precision, linearity, range, specificity, limit of detection (LOD), limit
of Quantization (LOQ) according to international conference on
IV
harmonization guidelines (ICHG). The method is very selective and
specific for the active ingredient and also is very sable. The
calibration curve was linear for the concentrations in the range of
80%, 120% the correlation coefficient R2 as found to be 0.9999 the
LOD and LOQ as found to be to be 143.13 μg/ml and 433.72 μg/ml
respectively , the recoveries of accuracy as found to be 99%, 100%,
99.5%.
This method is recommended for the future used for routine analysis
of Ciprofloxacin in pharmaceutical formulation in pharmaceutical
industry, due to its simplicity specificity, accuracy, and precision.
